Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
B55R1 and B55R2 in Non-proliferative Diabetic Retinopathy
NCT07230184Phase 4Completed
- Sponsor
- AJU PHARM Co., Ltd.
- Start
- Apr 2022
- Primary completion
- Aug 2023
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial (2 arms), sponsored by AJU PHARM Co., Ltd. Primary endpoint: Proportion of subjects achieving a ≥1-step improvement in hard exudate grade at 24 weeks. Started Apr 2022; status: completed.
Beyond the preview
Go deeper on NCT07230184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07230184.